Does semaglutide's appetite suppression increase the risk of under-fueling?

Semaglutide is a potent glucagon-like peptide-1 (GLP-1) receptor agonist that has fundamentally changed the landscape of weight management by targeting the physiological drivers of hunger. By mimicking endogenous GLP-1, it exerts profound effects on energy balance through both central and peripheral pathways.

Clinical evidence and energy intake

• Appetite suppression: Randomized controlled trials (RCTs) utilizing the 2.4 mg dose of semaglutide consistently demonstrate significant improvements in "control of eating" and substantial reductions in subjective appetite scores compared to placebo.
• Reduced caloric consumption: The drug leads to a marked decrease in spontaneous (ad libitum) energy intake. Clinical data indicate that users often experience shifts in food preference, specifically a decreased craving for energy-dense, fatty foods.
• Weight loss outcomes: These reductions in intake translate to robust weight loss, typically ranging from 9.6% to over 17% of total body weight, driven by a sustained, often unintentional, caloric deficit.

Mechanistic insights

• Neurological targeting: Semaglutide accesses the brain through circumventricular organs, directly activating GLP-1 receptors in the hypothalamus, brainstem, and septal nucleus to promote satiety and suppress hunger.
• Gastrointestinal effects: Beyond the central nervous system, semaglutide slows gastric emptying, which prolongs the sensation of fullness after meals and contributes to the overall reduction in daily energy intake.

Physiological implications and under-fueling

• Low Energy Availability (LEA): While direct clinical studies on Low Energy Availability in semaglutide users are limited, the mechanism of potent appetite suppression creates a plausible risk for under-fueling. This is defined as energy intake failing to meet physiologic demands after accounting for exercise expenditure.
• Lean mass preservation: Treatment often results in the loss of lean muscle mass alongside fat mass. This phenomenon suggests that without careful nutritional monitoring and protein intake, the significant caloric restriction may outpace the body’s metabolic requirements for tissue maintenance.

Bottom line

Semaglutide effectively reduces appetite and energy intake via central GLP-1 receptor activation. While this is the primary driver of therapeutic weight loss, the intensity of appetite suppression makes under-fueling relative to physiologic demand a plausible risk, particularly in active individuals, necessitating monitoring of nutritional adequacy and lean mass.